Black Diamond Therapeutics, Inc. — Director's Dealing 2021

Jan 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Black Diamond Therapeutics, Inc. (BDTX)
CIK: 0001701541
Period of Report: 2021-01-19

Reporting Person: Dhingra Kapil (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-19	Stock Option (Right to Buy)	$27.45	A	29842	Acquired	2031-01-19	Common Stock (29842)	Direct

Footnotes

F1: This option shall vest and become exercisable in thirty-six (36) equal monthly installments following the Grant Date.